{"id":95,"date":"2024-02-15T15:56:30","date_gmt":"2024-02-15T15:56:30","guid":{"rendered":"http:\/\/localhost\/sites\/aprea.loc\/?page_id=95"},"modified":"2026-05-13T12:57:15","modified_gmt":"2026-05-13T12:57:15","slug":"aprea-therapeutics-pipeline","status":"publish","type":"page","link":"https:\/\/aprea.com\/aprea-therapeutics-pipeline\/","title":{"rendered":"Pipeline"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"95\" class=\"elementor elementor-95\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-19deff99 e-con-full e-flex e-con e-parent\" data-id=\"19deff99\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-4efef32 e-con-full e-flex e-con e-child\" data-id=\"4efef32\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-62573b35 elementor-widget__width-initial elementor-widget-mobile__width-initial elementor-widget elementor-widget-heading\" data-id=\"62573b35\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">A Robust pipeline of <br>novel therapeutics<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-43cdafba e-con-full e-flex e-con e-parent\" data-id=\"43cdafba\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-57165cc5 elementor-widget-tablet__width-inherit elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"57165cc5\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_effect&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_level&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:7.79999999999999982236431605997495353221893310546875,&quot;sizes&quot;:[]},&quot;motion_fx_opacity_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:6,&quot;end&quot;:53}},&quot;motion_fx_opacity_direction&quot;:&quot;out-in&quot;,&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;tablet&quot;,&quot;mobile&quot;]}\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-307bc97 e-con-full e-flex e-con e-parent\" data-id=\"307bc97\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-d08cadd e-con-full e-grid e-con e-child\" data-id=\"d08cadd\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-b6297aa e-con-full e-flex e-con e-child\" data-id=\"b6297aa\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-69f9eb3 elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"69f9eb3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Aprea is focused on delivering breakthrough therapies for cancers with high unmet medical need. Our two lead programs are WEE1 inhibitor (APR-1051) and ATR inhibitor (ATRN-119)<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f37bfc6 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"f37bfc6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Our lead programs include APR-1051, a next-generation inhibitor of the WEE1 kinase, and ATRN-119, a novel macrocyclic ATR inhibitor. These two investigational therapies are the cornerstones of our precision medicine pipeline.<\/p><p>\u00a0<\/p><p>Both compounds were discovered internally at Aprea and are being developed by our experienced team of chemists, scientists, and clinicians. Together, they represent our commitment to advancing innovative treatments for cancer patients with unmet medical needs, while delivering meaningful impact to patients and generate long-term value for shareholders.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-72d11d1 e-con-full e-flex e-con e-child\" data-id=\"72d11d1\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-ce480e7 e-con-full e-flex e-con e-child\" data-id=\"ce480e7\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b6e7405 elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"b6e7405\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">A mission to increase the specificity and reduce the toxicity of DDR inhibitors<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-869867e elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"869867e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Our therapeutic assets\u2014and the proprietary technologies we use to validate them\u2014reflect our commitment to giving cancer patients more choices.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8ec76ba e-con-full e-flex e-con e-parent\" data-id=\"8ec76ba\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cc0f754 elementor-widget-tablet__width-inherit elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"cc0f754\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_effect&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_level&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:7.79999999999999982236431605997495353221893310546875,&quot;sizes&quot;:[]},&quot;motion_fx_opacity_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:6,&quot;end&quot;:53}},&quot;motion_fx_opacity_direction&quot;:&quot;out-in&quot;,&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;tablet&quot;,&quot;mobile&quot;]}\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f85960f e-con-full e-flex e-con e-parent\" data-id=\"f85960f\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-5a30f2f1 e-con-full e-flex e-con e-child\" data-id=\"5a30f2f1\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a27d0cd elementor-widget elementor-widget-html\" data-id=\"a27d0cd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"wp-block-table\">\n  <table>\n    <thead>\n      <tr>\n        <th width=\"86\">MOLECULE<\/th>\n        <th width=\"83\">SCHEDULE<\/th>\n        <th width=\"107\">ALTERATIONS<\/th>\n        <th width=\"112\">INDICATION<\/th>\n        <th width=\"102\">PRECLINICAL<\/th>\n        <th width=\"30\">IND<\/th>\n        <th width=\"55\">PHASE 1<\/th>\n        <th width=\"121\">ANTICIPATED MILESTONES<\/th>\n      <\/tr>\n    <\/thead>\n    <tbody>\n      <tr>\n        <td rowspan=\"4\">WEE1 Inhibitor APR-1051<\/td>\n        <td rowspan=\"4\">Oral QD<\/td>\n        <td>CCNE1, CCNE2, FBXW7, PPP2R1A<\/td>\n        <td>Advanced Solid Tumors<\/td>\n        <td colspan=\"3\" rowspan=\"4\" style=\"\n    background-image: url(\/wp-content\/uploads\/2025\/04\/after.png);\n    background-repeat: no-repeat;\n    background-size: 20px 115px;\n    background-position: center right 10px;\"><div class=\"rectangle\" style=\"width:90%; position: relative;\"><span style=\"color: #ffffff;position: absolute;left: 10px;top: 11px;\">Monotherapy<\/span>\n            <div class=\"triangle-right\" style=\"margin-left: 100%;\"><\/div>\n          <\/div><\/td>\n        <td rowspan=\"4\"><p>Potential Safety\/Efficacy Clinical Data<br \/>\n          2Q 2026<\/p>\n          <p>Complete Dose Escalation 2Q 2027<\/p><\/td>\n      <\/tr>\n      <tr style=\"\n    background-color: #c5c5c5;\n\">\n        <td>HPV+<\/td>\n        <td>Oropharyngeal Squamous Cell Carcinoma Cervical, Vaginal, or Vulvar Squamous Cell Carcinoma<\/td>\n      <\/tr>\n      <tr>\n        <td>KRAS<sup>G12\/13<\/sup> &amp; TP53\n<\/td>\n        <td>CRC<\/td>\n      <\/tr>\n      <tr style=\"\n    background-color: #c5c5c5;\">\n        <td>Regardless of Biomarker Status<\/td>\n        <td><p>Uterine Serous Carcinoma<\/p><\/td>\n      <\/tr>\n      <tr style=\"\n    background-color: #a1ba6d;\">\n        <td>ATR Inhibitor ATRN-119,<br>\n(Mosipasertib)<\/td>\n        <td>Oral QD<\/td>\n        <td><p>ATRi Synthetic Lethal Gene Alterations <\/p><\/td>\n        <td><p>Advanced Solid Tumors (Ovarian, CRC, Lung)<\/p>\n        <p>Hematological Cancers (AML, MDS)\n<\/p><\/td>\n        <td colspan=\"3\" style=\"\n    background-image: url(\/wp-content\/uploads\/2025\/04\/after.png);\n    background-repeat: no-repeat;\n    background-size: 20px 115px;\n    background-position: center right 10px;\"><div class=\"rectangle\" style=\"width:95%; position: relative;\"><span style=\"color: #ffffff;position: absolute;left: 10px;top: 11px;\">Monotherapy, RP2D Determined\n<\/span>\n            <div class=\"triangle-right\" style=\"margin-left: 100%;\"><\/div>\n          <\/div><\/td>\n        <td><p>Potential Collaborations On Combining ATRN-119 with ADCs, Chemo, Radiation or I\/O<br>\n2H 2026<\/p><\/td>\n      <\/tr>\n      <tr style=\"background-color: #cacaca;\">\n        <td>DYRK1 Inhibitor APR-1602<\/td>\n        <td>Oral<\/td>\n        <td>TBD<\/td>\n        <td><p>Solid Tumors &amp; Hematological Cancers<\/p><\/td>\n        <td colspan=\"3\"><div class=\"rectangle\" style=\"width:37%; position: relative;\"><span style=\"color: #ffffff;position: absolute;left: 10px;top: 11px;\">Monotherapy\n<\/span>\n            <div class=\"triangle-right\" style=\"margin-left: 100%;\"><\/div>\n          <\/div><\/td>\n        <td><p>Ready to Enter IND <br \/>\nEnabling Studies<br \/>\n4Q 2026<\/p><\/td>\n      <\/tr>\n    <\/tbody>\n  <\/table>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6fc31a0f elementor-align-center elementor-widget elementor-widget-button\" data-id=\"6fc31a0f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/aprea-therapeutics-clinical-trials\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn About Clinical Trials<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-49383979 e-con-full e-flex e-con e-parent\" data-id=\"49383979\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a27b710 elementor-widget-tablet__width-inherit elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"a27b710\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_effect&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_level&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:7.79999999999999982236431605997495353221893310546875,&quot;sizes&quot;:[]},&quot;motion_fx_opacity_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:6,&quot;end&quot;:53}},&quot;motion_fx_opacity_direction&quot;:&quot;out-in&quot;,&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;tablet&quot;,&quot;mobile&quot;]}\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-405df0c7 e-con-full e-flex e-con e-parent\" data-id=\"405df0c7\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-bc9a188 e-grid e-con-full e-con e-child\" data-id=\"bc9a188\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-3fec615 e-grid e-con-full e-con e-child\" data-id=\"3fec615\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ef126f7 elementor-widget elementor-widget-spacer\" data-id=\"ef126f7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c517c27 elementor-widget elementor-widget-heading\" data-id=\"c517c27\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">WEE1 Program: APR-1051<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-c896f67 e-con-full e-flex e-con e-child\" data-id=\"c896f67\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d4a822a elementor-widget elementor-widget-image\" data-id=\"d4a822a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"161\" height=\"161\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" data-src=\"https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo.png\" class=\"attachment-large size-large wp-image-620 lazyload\" alt=\"\" data-srcset=\"https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo.png 161w, https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo-150x150.png 150w\" sizes=\"(max-width: 161px) 100vw, 161px\" \/><noscript><img decoding=\"async\" width=\"161\" height=\"161\" src=\"https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo.png\" class=\"attachment-large size-large wp-image-620 lazyload\" alt=\"\" srcset=\"https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo.png 161w, https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo-150x150.png 150w\" sizes=\"(max-width: 161px) 100vw, 161px\" \/><\/noscript>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-220f050 elementor-widget elementor-widget-button\" data-id=\"220f050\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/aprea-therapeutics-clinical-trials\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn About Clinical Trials<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e5fa461 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e5fa461\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>WEE1 is a protein kinase that helps regulate the cell cycle by preventing abnormal progression. Specifically, WEE1 prevents the premature entry of cells into both the DNA synthetic (S phase) and cell division (mitosis) phases of the cell cycle, ensuring that cells only divide after properly duplicating and repairing their DNA. By preforming these functions, WEE1 plays a crucial role in maintaining genome stability and cell survival, epically during periods of rapid cell division, a hallmark of cancer. As a result, cancer cells are particularly reliant on WEE1 for growth and survival.<\/p><p>\u00a0<\/p><p>APR-1051 is an orally bioavailable, highly potent, and selective small molecule inhibitor of WEE1. APR-1051 has demonstrated strong anti-proliferative activity across multiple cancer cell lines and in mouse models. APR-1051 also exhibits favorable pharmacodynamic properties, including lower off-target inhibition of three members of the PLK family of kinases (PLK1, PLK2, and PLK3).<\/p><p>\u00a0<\/p><p>Preliminary results from the ongoing Phase 1 study provide early clinical proof-of-concept of APR-1051. In addition, APR-1051 has been well tolerated to date.<\/p><p>\u00a0<\/p><p>These results strengthen Aprea&#8217;s conviction that APR-1051 has the potential to deliver a favorable therapeutic window, supporting its potential to be a differentiated WEE1 kinase inhibitor for patients with genomically defined solid tumors who have limited treatment options.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-812a293 e-con-full e-flex e-con e-parent\" data-id=\"812a293\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8be9977 elementor-widget-tablet__width-inherit elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"8be9977\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_effect&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_level&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:7.79999999999999982236431605997495353221893310546875,&quot;sizes&quot;:[]},&quot;motion_fx_opacity_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:6,&quot;end&quot;:53}},&quot;motion_fx_opacity_direction&quot;:&quot;out-in&quot;,&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;tablet&quot;,&quot;mobile&quot;]}\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-dbefd16 e-grid e-con-full e-con e-child\" data-id=\"dbefd16\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-3573e1d e-grid e-con-full e-con e-child\" data-id=\"3573e1d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d962820 elementor-widget elementor-widget-spacer\" data-id=\"d962820\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6dff702 elementor-widget elementor-widget-heading\" data-id=\"6dff702\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><span class=\"elementor-heading-title elementor-size-default elementor-inline-editing pen\" data-elementor-setting-key=\"title\" data-pen-placeholder=\"Type Here...\" style=\"font-family: Freeman, sans-serif;font-size: 48px\">ATR Program: ATRN-119<\/span><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0a193d9 e-con-full e-flex e-con e-child\" data-id=\"0a193d9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d244749 elementor-widget elementor-widget-image\" data-id=\"d244749\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"161\" height=\"161\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" data-src=\"https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo.png\" class=\"attachment-large size-large wp-image-620 lazyload\" alt=\"\" data-srcset=\"https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo.png 161w, https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo-150x150.png 150w\" sizes=\"(max-width: 161px) 100vw, 161px\" \/><noscript><img decoding=\"async\" width=\"161\" height=\"161\" src=\"https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo.png\" class=\"attachment-large size-large wp-image-620 lazyload\" alt=\"\" srcset=\"https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo.png 161w, https:\/\/aprea.com\/wp-content\/uploads\/2025\/02\/Aprea_Logo-150x150.png 150w\" sizes=\"(max-width: 161px) 100vw, 161px\" \/><\/noscript>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-55e2654 elementor-widget elementor-widget-button\" data-id=\"55e2654\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/aprea-therapeutics-clinical-trials\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn About Clinical Trials<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0f8ba45 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"0f8ba45\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The ataxia telangiectasia and Rad3-related (ATR) kinase is a key regulator of the DNA damage response, playing a central role in maintaining genomic instability and controlling cell proliferation. By coordinating cellular responses to replication stress and damage, ATR allows cancer cells to survive despite rapid proliferation and defective DNA repair mechanisms. Inhibiting ATR disrupts these survival pathways, potentially making cancer cells more vulnerable to treatment. To leverage this vulnerability, Aprea Therapeutics has developed a highly potent and selective ATR inhibitor, ATRN-119, the first macrocyclic ATR inhibitor to enter clinical trials, representing a novel class of targeted therapy.<\/p><p>\u00a0<\/p><p>During 4Q 2025 Aprea determined the recommended Phase 2 dose (RP2D) to be 1,100 mg for the once daily dosing for ATRN-119. Following RP2D determination, Aprea is currently in discussions with leading academic institutions to evaluate ATRN-119 in combination with radiation in HPV-positive head and neck cancer. Additional investigator-led studies evaluating ATRN-119 with immuno-oncology therapies and antibody-drug conjugates are also being explored.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-521edbe8 e-con-full e-flex e-con e-parent\" data-id=\"521edbe8\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-408fb1bb elementor-widget-tablet__width-inherit elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"408fb1bb\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_effect&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_level&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:7.79999999999999982236431605997495353221893310546875,&quot;sizes&quot;:[]},&quot;motion_fx_opacity_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:6,&quot;end&quot;:53}},&quot;motion_fx_opacity_direction&quot;:&quot;out-in&quot;,&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;tablet&quot;,&quot;mobile&quot;]}\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-689c2aca e-con-full e-flex e-con e-parent\" data-id=\"689c2aca\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-95ef033 elementor-widget-tablet__width-inherit elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"95ef033\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_effect&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_level&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:7.79999999999999982236431605997495353221893310546875,&quot;sizes&quot;:[]},&quot;motion_fx_opacity_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:6,&quot;end&quot;:53}},&quot;motion_fx_opacity_direction&quot;:&quot;out-in&quot;,&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;tablet&quot;,&quot;mobile&quot;]}\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>A Robust pipeline of novel therapeutics Aprea is focused on delivering breakthrough therapies for cancers with high unmet medical need. Our two lead programs are WEE1 inhibitor (APR-1051) and ATR inhibitor (ATRN-119) Our lead programs include APR-1051, a next-generation inhibitor of the WEE1 kinase, and ATRN-119, a novel macrocyclic ATR inhibitor. These two investigational therapies [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-95","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/aprea.com\/wp-json\/wp\/v2\/pages\/95","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aprea.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aprea.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aprea.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aprea.com\/wp-json\/wp\/v2\/comments?post=95"}],"version-history":[{"count":24,"href":"https:\/\/aprea.com\/wp-json\/wp\/v2\/pages\/95\/revisions"}],"predecessor-version":[{"id":1549,"href":"https:\/\/aprea.com\/wp-json\/wp\/v2\/pages\/95\/revisions\/1549"}],"wp:attachment":[{"href":"https:\/\/aprea.com\/wp-json\/wp\/v2\/media?parent=95"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}